Stocks Health care KNSA
NASDAQ · Health careKiniksa Pharmaceuticals International, plc (KNSA)
Kiniksa Pharmaceuticals International, plc brought in $754M of revenue over the twelve months to March 31, 2026, up 56.7% from a year earlier. Net income was $73.1M, a net margin of 9.7%. Operating cash flow minus capital spending left $136.4M of free cash flow in fiscal 2025. At March 31, 2026 it held $190M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 28, 2026.
What Kiniksa Pharmaceuticals International, plc does
Kiniksa Pharmaceuticals International, plc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KNSA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $677.6M | $59M | $0.75 | $136.4M |
| 2024 | $423.2M | -$43.2M | -$0.60 | $25.4M |
| 2023 | $270.3M | $14.1M | $0.20 | $13.2M |
| 2022 | $220.2M | $183.4M | $2.60 | $5.7M |
| 2021 | $38.5M | -$157.9M | -$2.30 | -$126.7M |
| 2020 | n/a | -$161.4M | -$2.61 | -$136.8M |
Latest SEC filings
What Kiniksa Pharmaceuticals International, plc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- July 29, 2026Passive stake (5% or more) SCHEDULE 13G
- July 28, 2026Quarterly report 10-Q · period to June 30, 2026
- July 28, 2026
- May 29, 2026
- May 26, 2026Activist stake changed SCHEDULE 13D/A
- May 26, 2026
- May 6, 2026Passive stake changed SCHEDULE 13G/A
- May 1, 2026
- April 28, 2026Quarterly report 10-Q · period to March 31, 2026
- April 28, 2026
Questions about KNSA
What does Kiniksa Pharmaceuticals International, plc do?
Kiniksa Pharmaceuticals International, plc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KNSA.
Is Kiniksa Pharmaceuticals International, plc profitable?
Yes. Over the twelve months to March 31, 2026 it reported net income of $73.1M on revenue of $754M, a net margin of 9.7%.
How much revenue does Kiniksa Pharmaceuticals International, plc make?
Over the twelve months to March 31, 2026 Kiniksa Pharmaceuticals International, plc reported revenue of $754M. That is 56.7% more than a year earlier.
When did Kiniksa Pharmaceuticals International, plc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 28, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 3, 2026.
Similar companies
Follow KNSA
Get an email when Kiniksa Pharmaceuticals International, plc files with the SEC: results, executive changes, material agreements and annual reports.
Follow KNSA: get an email when it filesWhere the numbers come from
Financial figures are the values Kiniksa Pharmaceuticals International, plc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.